A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508349-42-00

Acronym

FURMO-002

Enrollment

Registered

2024-07-11

Start date

2022-10-18

Completion date

Unknown

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026